In early 2021, Ashley Addiction Treatment will welcome new leadership with the promotion of Alex Denstman, MBA and Greg Hobelmann, M.D., M.P.H to Joint CEOs

After nearly a year of careful consideration and strategic planning, Ashley’s Board of Directors has appointed two successors to our current President and CEO, Dave Nassef, to take on the role of Joint CEOs, effective March 1, 2021. Ashley’s new Joint CEOs will be Alex Denstman, current SVP and Chief Growth Officer, and Dr. Greg Hobelmann, current SVP and Chief Medical and Clinical Officer. By promoting these two individuals to lead Ashley, the Board and leadership is delivering on our unwavering commitment to evolve with the industry and the disease of addiction to bring value, innovation, and results to our patients and community.

Learn more about the official announcement here.

Learn more about Alex and Greg here.

Empowered to Continue Evolving and Innovating

The disease of addiction continues to evolve and grow more complex. We’re evolving to stay ahead of it. As our patients’ needs evolve, we’re committed to evolving, too.

At Ashley, we pride ourselves on being industry leaders in substance use disorder treatment. We embody a commitment to not only deliver the highest quality of care to our patients, but also to continue to evolve as the disease of addiction evolves, and apply outcomes from our research to innovative treatment methods.

Under the leadership of our new Joint CEOs, Ashley will continue to innovate and lead the industry in treating substance use disorder. Our strong partnerships with research institutions such as Johns Hopkins will ensure greater opportunities to make significant achievements in the battle against substance use disorder.

Upholding a Legacy of Visionary Leaders

Ashley was co-founded 38 years ago by Mae Ashley Abraham and Father Joseph C. Martin, two passionate, visionary leaders, who implemented a treatment model that pioneered many methods still in use today. That legacy has lived on through nearly four decades under compassionate leadership, resulting in the successful treatment of over 45,000 people. This legacy will continue under this new co-leadership. Alex and Greg are dedicated professionals and highly regarded leaders in this field. In this collaborative partnership, our organization will be mission-led, sustainable, and empowered to continue changing lives for decades to come.

What’s Next for Ashley

Ashley remains dedicated to providing innovative care to treat substance use disorders across many proven, holistic programs, each of which is customized to the individual needs of our patients. We’re confident that in this new chapter of Ashley’s leadership, we will continue to deliver value and results, and uphold the legacy of our founders.

As we roll out this transition later this year and in 2021, we invite you to follow along by subscribing to Ashley’s newsletter for periodic updates.

Sign up below to receive the Ashley newsletter.